Diagnostic and prognostic value of fas and telomeric-repeat binding factor-1 genes in adrenal tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 8, 2003, Pages 3690-3693

  Kanauchi, Hajime ^a,e   Wada, Nobuyuki ^a,f   Ginzinger, David G ^b   Yu, Mamie ^b   Wong, Mariwil G ^c   Clark, Orlo H ^c   Duh, Quan Yang ^d  

^a Endocrine Surgical Oncology Fellows   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIBODY; GENE PRODUCT; PROTEIN BCL XL; TELOMERIC REPEAT BINDING FACTOR 1; UNCLASSIFIED DRUG;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL HYPERPLASIA; ADRENAL TUMOR; ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; INFANT; MALE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERE;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ANTIGENS, CD95; APOPTOSIS; BCL-X PROTEIN; DNA, COMPLEMENTARY; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TELOMERIC REPEAT BINDING PROTEIN 1;

EID: 0042384571     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020965     Document Type: Article

References (30)

1. Vassilopoulou-Sellin R, Schultz PN 2001 Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 92:1113-1121
2. Barnett Jr CC, Varma DG, El-Naggar AK, Dackiw APB, Porter GA, Pearson AS, Kudelka AP, Gagel RF, Evans DB, Lee JE 2000 Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery 128:973-983
3. Weiss LM, Medeiros LJ, Vickery Jr AL 1989 Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202-206
4. Gicquel C, Bertherat J, Le Bouc Y, Bertagna X 2000 Pathogenesis of adrenocortical incidentalomas and genetic syndromes associated with adrenocortical neoplasms. Endocrinol Metab Clin North Am 29:1-13
5. Stratakis CA, Chrousos GP 2000. Adrenal cancer. Endocrinol Metab Clin North Am 29:15-25
6. Kanauchi H, Wada N, Clark OH, Duh Q-Y 2002 Apoptosis regulating genes, bcl-2 and box, and human telomerase reverse transcriptase (hTERT) mRNA expression in adrenal tumors: possible diagnostic and prognostic importance. Surgery 132:1021-1026
7. Agarwal R, Talati M, Lambert W, Clark AF, Wilson SE, Agarwal N, Wordinger RJ 1999 Fas-activated apoptosis and apoptosis mediators in human trabecular meshwork cells. Exp Eye Res 68:583-590
8. Heid CA, Stevens J, Lival KJ, Willams PM 1996 Real time quantitative PCR. Genome Res 6:986-994
9. Ginzinger DG, Godfrey TE, Nigro J, Moore II DH, Suzuki S, Pallavicini MG, Gray JW, Jensen RH 2000 Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res 60:5405-5409
10. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB 1993 bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608
11. Nagata S, Golstein P 1995 The Fas death factor. Science 267:1449-1456
12. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G 2000 Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 292:225-232
13. Basolo F, Fiore L, Baldanzi A, Giannini R, Dell'Omodarme M, Fontanini G, Pacini F, Danesi R, Miccoli P, Toniolo A 2000 Suppression of Fas expression and down-regulation of Fas ligand in highly aggressive human thyroid carcinoma. Lab Invest 80:1413-1419
14. Minn AJ, Rudin CM, Boise LH, Thompson CB 1995 Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86:1903-1910
15. Wang DG, Johnston CE, Marley JJ, Phenix KV, Atkinson AB, Russell CF, Buchanan KD 1997 Expression of the apoptosis-suppressing gene BCL-2 in pheochromocytoma is associated with the expression of C-MYC. J Clin Endocrinol Metab 82:1949-1952
16. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dorken B 1995 Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60:854-859
17. Oltvai ZN, Milliman CL, Korsmeyer SJ 1993 Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619
18. Wolkersdorfer GW, Marx C, Lohmann T, Brauer S, Schroder S, Brown J, Mitsiades N, Chrousos GP, Bornstein SR 1998 The mercy of adrenocortical tumor cells on lymphocytes. Endocr Res 24:711-716
19. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB 1992 Telomere end-replication problem and cell aging. J Mol Biol 225:951-960
20. Zeiger MA, Smallridge RC, Clark DP, Liang CK, Carty SE, Watson CG, Udelsman R, Saji M 1999 Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Surgery 126:1195-1198
21. Brousset P, Chaouche N, Leprat F, Branet-Brousset F, Trouette H, Zenou RC, Merlio JP, Delsol G 1997 Telomerase activity in human thyroid carcinomas originating from the follicular cells. J Clin Endocrinol Metab 82:4214-4216
22. Mannelli M, Gelmini S, Arnaldi G, Becherini L, Bemporad D, Crescioli C, Pazzagli M, Mantero F, Serio M, Orlando C 2000 Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas. J Clin Endocrinol Metab 85:468-470
23. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW 1994 Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015
24. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR 1998 Telomerase activity, in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts Cancer Res 58:4168-4172
25. Smogorzewska A, van Steensel B, Bianchi A, Oelmann S, Schaefer MR, Schnapp G, de Lange T 2000 Control of human telomere length by TRF1 and TRF2. Mol Cell Biol 20:1659-1668
26. Kammori M, Nakamura KI, Kawahara M, Mimura Y, Kaminishi M, Takubo K 2002 Telomere shortening with aging in human thyroid and parathyroid tissue. Exp Gerontol 37:513-521
27. Kammori M, Takubo K, Nakamura K, Furugouri E, Endo H, Kanauchi H, Mimura Y, Kaminishi M 2000 Telomerase activity and telomere length in benign and malignant human thyroid tissues. Cancer Lett 159:175-181
28. van Steensel B, de Lange T 1997 Control of telomere length by the human telomeric protein TRF1. Nature 385:740-743
29. Nakamura K, Furugori E, Esaki Y, Arai T, Sawabe M, Okayasu I, Fujiwara M, Kammori M, Mafune K, Kato M, Oshimura M, Sasajima K, Takubo K 2000 Correlation of telomere lengths in normal and cancers tissue in the large bowel. Cancer Lett 158:179-184
30. Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R, Vidaud M 2000 Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6:452-459